@article {Riemersma2021.07.31.21261387, author = {Kasen K. Riemersma and Luis A. Haddock III and Nancy A. Wilson and Nicholas Minor and Jens Eickhoff and Brittany E. Grogan and Amanda Kita-Yarbro and Peter J. Halfmann and Hannah E. Segaloff and Anna Kocharian and Kelsey R. Florek and Ryan Westergaard and Allen Bateman and Gunnar E. Jeppson and Yoshihiro Kawaoka and David H. O{\textquoteright}Connor and Thomas C. Friedrich and Katarina M. Grande}, title = {Shedding of Infectious SARS-CoV-2 Despite Vaccination}, elocation-id = {2021.07.31.21261387}, year = {2022}, doi = {10.1101/2021.07.31.21261387}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The SARS-CoV-2 Delta Variant of Concern is highly transmissible and contains mutations that confer partial immune escape. The emergence of Delta in North America caused the first surge in COVID-19 cases after SARS-CoV-2 vaccines became widely available. To determine whether individuals infected despite vaccination might be capable of transmitting SARS-CoV-2, we compared RT-PCR cycle threshold (Ct) data from 20,431 test-positive anterior nasal swab specimens from fully vaccinated (n = 9,347) or unvaccinated (n=11,084) individuals tested at a single commercial laboratory during the interval 28 June {\textendash} 1 December 2021 when Delta variants were predominant. We observed no significant effect of vaccine status alone on Ct value, nor when controlling for vaccine product or sex. Testing a subset of low-Ct (\<25) samples, we detected infectious virus at similar rates, and at similar titers, in specimens from vaccinated and unvaccinated individuals. These data indicate that vaccinated individuals infected with Delta variants are capable of shedding infectious SARS-CoV-2 and could play a role in spreading COVID-19.Competing Interest StatementAmanda Kita-Yarbro owns 25 shares of Pfizer stock.Funding StatementThis work was supported by Centers for Disease Control and Prevention contracts 75D30120C09870 and 75D30121C11060 to D.H.O and T.C.F. The authors are also members of the Upper Midwest Regional Accelerator for Genomic Surveillance funded by the Rockefeller Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Wisconsin-Madison IRB office has confirmed that this project qualifies as public health surveillance activities as defined in the Common Rule, 45 CFR 46.102(l)(2). As such, the project is not deemed to be research regulated under the Common Rule and therefore, does not require University of Wisconsin-Madison IRB review and oversight. The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and processing workflows are available at https://go.wisc.edu/p22l16. To protect potentially personally identifiable information, the publicly available dataset contains only PCR Ct values, vaccine status, age, sex, manufacturer, symptom status, virus culture status, and days from symptom onset to testing for each specimen.}, URL = {https://www.medrxiv.org/content/early/2022/07/05/2021.07.31.21261387}, eprint = {https://www.medrxiv.org/content/early/2022/07/05/2021.07.31.21261387.full.pdf}, journal = {medRxiv} }